These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 19563238)
1. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B; AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238 [TBL] [Abstract][Full Text] [Related]
2. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. Ross LL; Rouse E; Gerondelis P; DeJesus E; Cohen C; Horton J; Ha B; Lanier ER; Elion R; J Antimicrob Chemother; 2010 Feb; 65(2):307-15. PubMed ID: 20008905 [TBL] [Abstract][Full Text] [Related]
3. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. Khanlou H; Yeh V; Guyer B; Farthing C AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380 [TBL] [Abstract][Full Text] [Related]
4. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS; J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763 [TBL] [Abstract][Full Text] [Related]
5. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study. Elion R; Cohen C; DeJesus E; Redfield R; Gathe J; Hsu R; Yau L; Ross L; Ha B; Lanier RE; Scott T; HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898 [TBL] [Abstract][Full Text] [Related]
6. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Ait-Khaled M; Rakik A; Griffin P; Cutrell A; Fischl MA; Clumeck N; Greenberg SB; Rubio R; Peters BS; Pulido F; Gould J; Pearce G; Spreen W; Tisdale M; Lafon S; Antivir Ther; 2002 Mar; 7(1):43-51. PubMed ID: 12008787 [TBL] [Abstract][Full Text] [Related]
7. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B; HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978 [TBL] [Abstract][Full Text] [Related]
8. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919 [TBL] [Abstract][Full Text] [Related]
9. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827 [TBL] [Abstract][Full Text] [Related]
10. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316 [TBL] [Abstract][Full Text] [Related]
11. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418 [TBL] [Abstract][Full Text] [Related]
12. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
13. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610 [TBL] [Abstract][Full Text] [Related]
14. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE; HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008 [TBL] [Abstract][Full Text] [Related]
15. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476 [TBL] [Abstract][Full Text] [Related]
16. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847 [TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine. Khanlou H; Farthing C AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045 [No Abstract] [Full Text] [Related]
18. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485 [TBL] [Abstract][Full Text] [Related]
19. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764 [TBL] [Abstract][Full Text] [Related]
20. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only? Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]